Evidence map›Paper›PMID 40530155›Full record

ArticleTranslational cancer research2025

Construction and validation of a clinical prognostic model for frontal glioblastoma: a real-world clinical study based on radiation therapy.

Shuai Hao, Jialing Liu, Jingjing Tuo, Li Wang, Wei Li, Ming Liu, Pengzhan Shuang, Nan Li

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuai Hao *Center of Oncology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.ORCID https://orcid.org/0009-0005-4727-4177
Jialing Liu *Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center of Caner, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Jingjing Tuo *Department of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Li WangDepartment of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Wei LiDepartment of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Ming LiuDepartment of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Pengzhan ShuangDepartment of Anesthesiology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Nan LiDepartment of Oncology, Hebei Medical University Third Hospital, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma has high malignancy, treatment challenge, poor prognosis and survival. It takes place mostly in the frontal lobe, and it significantly impacts late-life activities. Therefore, the establishment of a survival model for frontal glioblastoma patients is of great significance for optimizing the treatment for patients. The aim of this study is to identify risk factors for frontal glioblastoma, to construct survival models, and to provide strong evidence for patients and doctors to apply radiotherapy to frontal glioblastoma. Methods: Independent risk factors for frontal glioblastoma patients were identified and survival models were constructed based on information obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Clinical data on patients pathologically diagnosed with frontal glioblastoma were screened. A nomogram was constructed based on the training group to verify the clinical validity of the model. Results: A total of 2,063 patients were included. There were 1,444 patients assigned to the training group, according to a random number method, and the remaining 619 patients were included in the validation group. Cox multivariate analysis based on 1,444 data from the training group showed that age, tumor hemiorism, metastasis, surgery, chemotherapy and radiotherapy were significantly correlated with the prognosis, with P values less than 0.05. In the training group, the concordance index (C-index) for overall survival (OS) and cancer-specific survival (CSS) of the cohort was 0.712 and 0.710, respectively. Calibration, receiver operating characteristic curve and decision curve analysis for OS showed a good agreement between the actual and predicted probability of survival. A total of 225 cases were screened out for analysis after 1:1 matching with a caliper value of 0.02. The median survival time of patients receiving radiotherapy was 7 months and that of those without radiotherapy was 5 months, hazard ratio =1.067, P values less than 0.05. Conclusions: Age over 60 years old, space-occupying lesions across the midline, surgery not performed, radiotherapy not performed, and without chemotherapy are poor prognostic factors for frontal glioblastoma patients. Radiation therapy can significantly improve OS and CSS in frontal glioblastoma patients. The nomogram developed in this study has the potential for clinical application.

Indexed as

cancer-specific survival (CSS)Frontal glioblastomaoverall survival (OS)prognostic modelradiotherapy

Identifiers

PMID40530155
PMCPMC12170007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.